Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Neurocognitive Disorders, the DSM-5, and Informed Treatment Choices

neuroscienceCME Webcast

Premiere Date: Tuesday, May 6, 2014

This activity offers CE credit for:

  1. Physicians (CME)
  2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, May 6, 2015
Note: Credit Is No Longer Available


George T. Grossberg, MDGeorge T. Grossberg, MD (Moderator)
Samuel W. Fordyce Professor
Department of Neurology & Psychiatry
Department of Anatomy and Neurobiology
Department of Internal Medicine

Division of Geriatric Medicine 
Dementia, Health Aging
Saint Louis University School of Medicine
St. Louis, MO

W. Vaughn McCall, MD, MSW. Vaughn McCall, MD, MS 
Case Distinguished University Chair
Department of Psychiatry and Health Behavior
Executive Vice Dean
Medical College of Georgia
Augusta University
Augusta, GA

Statement of Need

Changes to the DSM-5 have modified the language used in evidence-based diagnostic criteria for dementia(1) and education for clinicians can accelerate both the adoption of this new language and how to apply these revisions to clinical practice.(1) The National Institutes of Health’s (NIH) National Institute on Aging Alzheimer’s Disease (NIAAD) Research Summit 2013 reported that the management of Alzheimer's disease needs to be viewed as a continuum that begins up to one decade before the symptoms form an obvious, clinical entity. The Summit further reported that Alzheimer's disease is a multifaceted disease, and there is much more that clinicians can do much more than they currently over the course of the disease to work to change its course.(2)

This enduring replay of the symposium presented at the AAGP Annual Meeting in Orlando, Florida will update clinicians on the new diagnostic language for neurocognitive disorders in DSM-5 for neurocognitive disorders and through the use of an interactive case challenge, demonstrate the implications of these changes for optimizing and informing clinical practice.

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5]. Alexandria, VA: American Psychiatric Association; 2013.
  2. Daviglus ML, Bell CC, Berrettini W, et al. NIH state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements. 2010;27(4):1-30. PMID: 20445638.

Activity Goal

Clinicians who participate in this activity will individualize a treatment plan that optimizes pharmacological and non-pharmacological approaches to suit each patient’s clinical assessments, a specific neurocognitive disorder diagnosis using the revised DSM-5 diagnostic language, and input from the patient and caregivers.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Review and apply changes in the DSM-5 as related to a diagnosis of neurocognitive disorders during annual assessments.
  • Implement the latest available treatment approaches as part of an individualized treatment plan aligned to the particular stage of Alzheimer’s disease including pharmacologic and non-pharmacologic approaches.

Financial Support

Provided by the American Association for Geriatric Psychiatry. Supported by an educational grant from Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories Inc.

Target Audience

Geriatric psychiatrists and psychiatrists

Credit Information

CME Credit (Physicians):
The American Association for Geriatric Psychiatry (AAGP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association for Geriatric Psychiatry (AAGP) designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit

Disclosure of Relevant Financial Relationships with Commercial Interests

American Association for Geriatric Psychiatry (AAGP) and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of AAGP and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.

AAGP and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Grossberg has disclosed that he has received research support from Accera, Inc.; Avanir Pharmaceuticals, Inc.; Noven Pharmaceuticals, Inc. He serves as a consultant to Forest Laboratories, Inc.; Lundbeck; Novartis Corporation; Otsuka Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Company. He serves on safety monitoring boards for Merck & Co. and Inc.; Newron.

Dr. McCall disclosed that he has received research support from Merck and National Institute of Mental Health (NIMH)

Disclosures were obtained from the AAGP staff: Nothing to Disclose.

Robert Kennedy (planning committee) has nothing to disclose.

Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.

Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

AAGP, CME Outfitters, LLC, the faculty, and Forest Research Institute, Inc., a wholly-owned subsidiary of Forest Laboratories Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download